All In Biotech

NDA 018140 · Hikma

Ativan

Lorazepam · Injection · Benzodiazepine

Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Jul 25, 1980

Approved uses

2

Original approval plus efficacy supplements

Registered trials

157

26 Phase 3, 11 recruiting

FAERS reports

180,741

139,049 serious, 26,091 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including Lorazepam Injection, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...

What it is approved for

From the label in effect Nov 9, 2026.

INDICATIONS AND USAGE Status Epilepticus Lorazepam Injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam Injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 5, 1997 Supplement 3 · Efficacy Review
  • Jul 25, 1980 Original approval · Type 3 - New Dosage Form
2 products under this application
  • ATIVAN · LORAZEPAM 4MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • ATIVAN · LORAZEPAM 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Lorazepam" as an intervention, any sponsor and status, largest first.

All 157 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue13,956
  • nausea13,776
  • drug ineffective12,685
  • diarrhoea10,751
  • off label use10,745
  • dyspnoea9,576
  • anxiety9,118
  • headache8,993
  • pain8,962
  • vomiting8,920
  • dizziness8,419
  • asthenia7,347

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,054
20053,435
20063,344
20073,141
20083,345
20094,196
20105,682
20116,022
20127,365
20135,867
20146,989
201510,425
201611,232
201711,734
201813,417
201913,188
202012,712
202111,112
202210,402
20239,527
20249,573
20258,976
20265,997

Recalls

6 FDA enforcement reports for this application.

  • Jul 22, 2025 · Class II · Ongoing

    Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

  • May 11, 2023 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.

  • Jul 11, 2022 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

  • Jul 11, 2022 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

  • Jul 11, 2022 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

  • Jul 11, 2022 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Shortages

FDA's drug shortage list.

  • Current · updated Oct 14, 2026

    Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25). Demand increase for the drug

  • Current · updated Oct 14, 2026

    Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25). Demand increase for the drug

  • Current · updated Oct 14, 2026

    Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10). Other

  • Current · updated Oct 14, 2026

    Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25). Demand increase for the drug

  • Current · updated Oct 14, 2026

    Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25). Demand increase for the drug

  • Current · updated Oct 14, 2026

    Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ativan* (Lorazepam)

2024 spending

$22.6M

Beneficiaries

1,633

6,598 claims

Per beneficiary

$13,820

$40.05 per unit

View as table
YearSpending
2020$22,372,746
2021$23,741,088
2022$24,316,631
2023$24,289,925
2024$22,568,403

Part B: Ativan* (Lorazepam*) · HCPCS J2060

2024 spending

$13K

Beneficiaries

3,752

9,674 claims

Per beneficiary

$3

2024 ASP limit $1.21 per unit

View as table
YearSpending
2020$19,411
2021$16,206
2022$13,456
2023$17,316
2024$12,588

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,061 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.